
News|Articles|December 24, 2025
The Hidden Cost of Health Misinformation
Author(s)Lana Pine
Fact checked by: Patrick Campbell
Clinicians across specialties explain how health misinformation is reshaping patient decisions, delaying care, and undermining trust.
Advertisement
Advertisement
Health information is everywhere. Patients can look up symptoms, medications, side effects, and treatment options in seconds before they ever speak with a clinician. While this access has empowered many people to take a more active role in their health, clinicians across specialties say it has also created a serious and growing challenge: health misinformation that shapes decisions, delays care, and undermines trust.
Related to this article

Diana Isaacs, PharmD, and Natalie Bellini, DNP, review OPTIMAL-DIABETES, SYNCHRONIZE-CVOT, and ATTAIN-OSA data from AHA 2026.

TRANSCEND-T2D-2 topline data show retatrutide lowered A1C more and produced over twice the weight loss of semaglutide 2 mg in type 2 diabetes.

Juanita Mora, MD, of Chicago Allergy Center discusses strategies from boosters and antiviral prophylaxis to specialist counseling.

Children receiving 50 nmol PVX108 increased their tolerated peanut dose 2.4-fold, with no treatment-related anaphylaxis in the phase 2 trial.

Ackerman and Bunick review 52-week AMETHYST data for litifilimab in refractory cutaneous lupus and make the case for dermatology-led CLE care.

Lawrence Eichenfield, MD, discusses phase 2 nemolizumab data in children aged 2 - 11 with atopic dermatitis, from caregiver-rated itch to sleep gains.

In this Q&A, Jennifer K. Priessnitz, MD, explains why FAERS reporting proportions should not drive biologic selection and what data are needed next.
Advertisement
Advertisement
